Which Weight Management Treatment Suits Your Needs?
Mounjaro vs Ozempic vs Wegovy: UK Stock Availability Comparison
The landscape of weight management medications has transformed dramatically, with reliable stock levels now available across all three major treatments. Wegovy represents the gold standard for prescription weight management, specifically licensed by the MHRA for this indication, whilst Mounjaro offers an innovative dual-hormone approach through its tirzepatide formulation. Ozempic, containing the same semaglutide as Wegovy, remains licensed exclusively for type 2 diabetes management in the UK. EverydayMeds maintains comprehensive stock levels of both Wegovy and Mounjaro, ensuring patients can access their prescribed treatment without interruption.
Our UK supply chain partnerships with Novo Nordisk and Lilly assurance consistent availability, eliminating the uncertainty that previously surrounded these innovative treatments. When comparing Mounjaro vs Ozempic vs Wegovy for accessibility, patients can now focus on clinical suitability rather than availability concerns. All five Wegovy doses remain in stock, from the 0.25mg starter dose through to the 2.4mg maintenance strength, with same robust supply assurance extending to Mounjaro's complete dose range.
Wegovy vs Mounjaro Pricing: Complete UK Cost Analysis
Understanding the investment required for each treatment helps inform your decision when weighing Mounjaro vs Ozempic vs Wegovy options. Wegovy pricing starts at £79.99 for the 0.25mg starter pen, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New patients benefit from code FIRST40 applied at checkout, whilst returning customers use DOSE25 to reach these final prices. Our bundle options provide supply security, with the Intro Duo (0.25mg & 0.5mg) available for £169.99, ensuring your first two months proceed smoothly.
Mounjaro follows a similar escalation structure, though pricing reflects its novel dual-hormone mechanism and distinct clinical profile. Both treatments qualify for our express prescriber review service, reducing standard 3-day processing to 24 hours for patients eager to commence treatment. When comparing the total investment across a full titration schedule, both Mounjaro vs Ozempic vs Wegovy considerations extend beyond individual pen costs to encompass the complete journey to maintenance dosing.
Clinical Evidence: Mounjaro vs Ozempic vs Wegovy Research
The STEP clinical trial programme established Wegovy's efficacy profile, with participants achieving approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). STEP 5 demonstrated sustained results over two years, whilst the SELECT trial revealed a 20% reduction in major cardiovascular events. These outcomes reflect Wegovy's targeted GLP-1 receptor agonism in patients following reduced-calorie diets and increased physical activity.
Mounjaro's clinical evidence stems from its SURMOUNT programme, evaluating tirzepatide's dual GIP and GLP-1 receptor activation. Direct head-to-head comparisons between trials remain inappropriate due to differing study designs, populations, and endpoints, making individual clinical assessment essential when choosing between these prescription-only medicines. Both treatments require specialist prescriber evaluation to determine optimal suitability for each patient's circumstances.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and food intake. Once injected weekly via the FlexTouch pen system, semaglutide activates GLP-1 receptors in the brain's appetite control centres, promoting enhanced satiety signals after smaller meals. This mechanism may help reduce food cravings and extend feelings of fullness, supporting adherence to reduced-calorie dietary plans. The treatment works synergistically with lifestyle modifications rather than replacing the need for dietary changes and increased physical activity. Clinical response typically develops gradually during the dose escalation phase, with optimal effects often observed at maintenance dosing levels.
EverydayMeds Ordering Process: Assessment to Delivery
Our streamlined process begins with a comprehensive 3-minute online clinical assessment, capturing your medical history, current medications, and weight management goals. Qualified prescribers review each application within our standard 3 working days timeframe, or 24 hours via our express service for urgent requirements. Once approved, your prescription-only medicine ships via next-day delivery using cold-chain transport to maintain the 2-8°C temperature requirements throughout transit. Each delivery includes detailed administration guidance, dose escalation schedules, and direct access to our clinical support team. Temperature-monitoring technology within our packaging ensures medication integrity from our GPhC-registered facilities (#9012878) directly to your door.
Storage and Practical Considerations for Daily Use
Wegovy requires refrigeration between 2-8°C before first use, though offers superior travel flexibility with 6 weeks room temperature storage capability once removed from the fridge. This storage advantage exceeds Mounjaro's 21-day room temperature limit, making Wegovy particularly suitable for frequent travellers or those with variable routine patterns. The FlexTouch delivery system provides consistent dosing through a simple once-weekly injection, with mandatory dose escalation preventing patients from advancing too rapidly. Each pen contains four doses, clearly marked for easy identification, whilst the thin 32-gauge needle minimises injection discomfort. Proper dose progression remains essential for tolerability, starting at 0.25mg and increasing monthly until reaching the 2.4mg maintenance level.
Mounjaro vs Ozempic vs Wegovy: UK Regulatory Status Comparison
Navigating the regulatory landscape proves crucial when comparing Mounjaro vs Ozempic vs Wegovy for weight management purposes. Wegovy holds specific MHRA licensing for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities, supported by NICE TA875 recommendations for specialist weight management programmes. Mounjaro has received similar weight management approval, offering patients an alternative mechanism through its dual-hormone approach. However, Ozempic maintains licensing exclusively for type 2 diabetes treatment, making its prescription for weight management inappropriate within UK regulatory frameworks.
Both Wegovy and Mounjaro carry Black Triangle status (▼), indicating MHRA additional monitoring requirements for these newer treatments. This enhanced surveillance reflects their recent market introduction rather than safety concerns, ensuring comprehensive post-marketing evaluation. Patients prescribed either treatment through EverydayMeds receive full regulatory compliance, with appropriate clinical oversight and monitoring protocols throughout their treatment journey.
Making Your Decision: Clinical Assessment and Next Steps
The choice between available treatments depends entirely on individual clinical circumstances, medical history, and treatment goals rather than availability concerns. Both Wegovy and Mounjaro are readily available from EverydayMeds, with experienced prescribers helping determine optimal suitability for your specific situation. Your clinical assessment will evaluate factors including current medications, previous weight management attempts, underlying health conditions, and lifestyle considerations that influence treatment selection. New customers can begin immediately using code FIRST40 at checkout, whilst our returning customer community benefits from DOSE25 savings on subsequent orders. Start your clinically-supervised weight management journey today at https://everydaymeds.co.uk/collections/wegovy, supported by our GPhC-registered pharmacy team and comprehensive ongoing clinical support throughout your treatment experience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
